Standard BioTools Inc. - Common Stock (LAB)
Healthcare › Laboratory Analytical Instruments
Price History
Feb 9, 2026 — May 10, 2026Investment Snapshot
- Trading 38% below Graham Number ($1.65) — significant margin of safety
- Piotroski F-Score 5/9 — moderate financial health
- ROE of 5.9% — below-average profitability
- Revenue declining 51% annually
Standard BioTools Inc. - Common Stock (LAB) is a Healthcare company operating in Laboratory Analytical Instruments, listed on the NASDAQ , with a market capitalisation of $398 million . Key value metrics: P/E ratio 12.1, P/B ratio 0.71, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Standard BioTools Inc. - Common Stock — Fundamental Analysis Summary
Standard BioTools Inc. - Common Stock (LAB) is trading 38% below its Graham Number of $1.65 — a significant margin of safety by Benjamin Graham's standard. The stock carries a reasonable trailing P/E ratio of 12.1x.
On financial health, LAB shows a moderate Piotroski F-Score of 5/9, and modest return on equity of 5.9% (sector average: -20.6%), and minimal leverage with a debt-to-equity ratio of 0.00.
StockPik's composite Value Score for LAB is 100/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
LAB reports a solid gross margin of 49.5% (sector average: 40.1%) and a negative operating margin of -100.8%.
LAB shows revenue declining at 51% year-over-year, with earnings growing at 46%.